[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:fibroblast-growth-factor-receptor-3":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Fibroblast Growth Factor Receptor 3",15,12,[8,16,23,29,35,41,48,54,60,66,72,78,84,91,97],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05208307","Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma",[12],"Phase 2","RECRUITING","2026-08-26T02:17:40.683658Z","2026-05-05T02:43:29.069274Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07218380","A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract",[20],"Phase 3","2026-08-26T02:16:16.995720Z","2026-05-05T02:43:28.563241Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07126262","A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to \u003C 36 Months",[12],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:28.339822Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06995677","Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer",[12],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:28.212310Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06207799","Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma",[12],"2026-08-26T02:17:59.904383Z","2026-05-05T02:43:28.173865Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT06915753","Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF\u002FFGFR Pathway Aberrations",[45],"Phase 1","2026-08-26T02:15:45.413021Z","2026-05-05T02:43:27.835984Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06842355","A Study of TYRA-300 in Children With Achondroplasia: BEACH301",[12],"2026-08-26T02:19:18.331180Z","2026-05-05T02:43:27.294738Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05614739","FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3",[45],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:26.956478Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT07169279","Interventional Study of Infigratinib in Children \u003C 3 Years Old With Achondroplasia (ACH)",[12],"2026-08-26T02:18:47.742071Z","2026-05-05T02:35:31.749384Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT04153422","IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies",[12],"2026-08-26T02:16:28.221034Z","2026-04-29T02:57:57.110373Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06874335","A Phase 1 Study of BHV-1530 in Advanced Solid Tumors",[45],"2026-08-26T02:17:07.954622Z","2026-07-19T19:36:05.062317Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06410976","Prospective Clinical Assessment Study in Children With Hypochondroplasia",[],"2026-08-26T02:17:16.126291Z","2026-05-13T02:55:06.489808Z",{"nct_id":85,"title":86,"phases":87,"status":88,"updated_at":89,"content_modified":90},"NCT05145010","Extension Study of Infigratinib in Children With Achondroplasia (ACH)",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:15:39.267524Z","2026-06-16T05:54:07.978306Z",{"nct_id":92,"title":93,"phases":94,"status":88,"updated_at":95,"content_modified":96},"NCT07393373","Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia",[12],"2026-08-26T02:18:58.958025Z","2026-06-16T05:54:07.881623Z",{"nct_id":98,"title":99,"phases":100,"status":88,"updated_at":102,"content_modified":103},"NCT06873035","An Interventional Study of Infigratinib in Children With Hypochondroplasia",[101],"Phase 2\u002FPhase 3","2026-08-26T02:15:29.632183Z","2026-06-16T05:54:07.784396Z"]